Hemodiafiltration improves red blood cell lifespan in patients with end‐stage renal disease

Abstract

Abstract Introduction Uremic toxin‐induced shortening of red blood cell (RBC) lifespan is an important mechanism of anemia in end‐stage renal disease (ESRD). Conventional hemodialysis does not improve RBC lifespan; the efficacy of hemodiafiltration (HDF) for alleviating RBC lifespan has not yet been evaluated in patients with ESRD. Methods Twenty‐three patients with ESRD in maintenance hemodialysis were enrolled. Baseline data for sex, age, dialysis vintage, pre‐dialysis hemoglobin (Hb), blood urea nitrogen (BUN), intact parathyroid hormone (iPTH), single pool Kt/V (spKt/V), and plasma indophenol sulfate (IS) were collected. RBC lifespans before and after one session of HDF were compared. The resultant differences were subjected to correlational analyses with baseline data. Results RBC lifespan increased from 73 (66, 89) days at baseline to 77 (71, 102) days after a single HDF treatment ( p = 0.034). Meanwhile, plasma IS concentration decreased from 113.05 (80.67, 133.05) mg/L to 83.87 (62.98, 96.78) mg/L ( p < 0.001). RBC lifespan increases correlated negatively with Hb levels. Conclusions A single HDF treatment improved RBC lifespan in ESRD patients on maintenance hemodialysis, with more severe pre‐HDF anemia at baseline being associated with greater increases in RBC lifespan.